These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21334602)

  • 1. Using brain imaging measures in studies of procognitive pharmacologic agents in schizophrenia: psychometric and quality assurance considerations.
    Barch DM; Mathalon DH
    Biol Psychiatry; 2011 Jul; 70(1):13-8. PubMed ID: 21334602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standardization, integration, and sharing-leveraging research investments.
    Insel TR; Morris SE; Heinssen RK
    Biol Psychiatry; 2011 Jul; 70(1):5-6. PubMed ID: 21672648
    [No Abstract]   [Full Text] [Related]  

  • 3. Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders.
    Carter CS; Barch DM; Bullmore E; Breiling J; Buchanan RW; Butler P; Cohen JD; Geyer M; Gollub R; Green MF; Jaeger J; Krystal JH; Moore H; Nuechterlein K; Robbins T; Silverstein S; Smith EE; Strauss M; Wykes T
    Biol Psychiatry; 2011 Jul; 70(1):7-12. PubMed ID: 21529781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain mapping biomarkers of socio-emotional processing in schizophrenia.
    Taylor SF; MacDonald AW;
    Schizophr Bull; 2012 Jan; 38(1):73-80. PubMed ID: 21965468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CNTRICS imaging biomarkers final task selection: Long-term memory and reinforcement learning.
    Ragland JD; Cohen NJ; Cools R; Frank MJ; Hannula DE; Ranganath C
    Schizophr Bull; 2012 Jan; 38(1):62-72. PubMed ID: 22102094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CNTRICS imaging biomarkers selection: Working memory.
    Barch DM; Moore H; Nee DE; Manoach DS; Luck SJ
    Schizophr Bull; 2012 Jan; 38(1):43-52. PubMed ID: 22080498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CNTRICS imaging biomarker selections: Executive control paradigms.
    Carter CS; Minzenberg M; West R; Macdonald A
    Schizophr Bull; 2012 Jan; 38(1):34-42. PubMed ID: 22114099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative.
    Barch DM; Carter CS;
    Schizophr Bull; 2008 Jul; 34(4):613-8. PubMed ID: 18499705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative.
    Carter CS; Barch DM
    Schizophr Bull; 2007 Sep; 33(5):1131-7. PubMed ID: 17630405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of cognitive impairment in schizophrenia.
    Goff DC; Hill M; Barch D
    Pharmacol Biochem Behav; 2011 Aug; 99(2):245-53. PubMed ID: 21115035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcranial magnetic stimulation: a neuroscientific probe of cortical function in schizophrenia.
    McClintock SM; Freitas C; Oberman L; Lisanby SH; Pascual-Leone A
    Biol Psychiatry; 2011 Jul; 70(1):19-27. PubMed ID: 21571254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models.
    Moore H; Geyer MA; Carter CS; Barch DM
    Neurosci Biobehav Rev; 2013 Nov; 37(9 Pt B):2087-91. PubMed ID: 24090823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative.
    Carter CS; Barch DM; Buchanan RW; Bullmore E; Krystal JH; Cohen J; Geyer M; Green M; Nuechterlein KH; Robbins T; Silverstein S; Smith EE; Strauss M; Wykes T; Heinssen R
    Biol Psychiatry; 2008 Jul; 64(1):4-10. PubMed ID: 18466880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visual perception and its impairment in schizophrenia.
    Butler PD; Silverstein SM; Dakin SC
    Biol Psychiatry; 2008 Jul; 64(1):40-7. PubMed ID: 18549875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CNTRICS final biomarker selection: Control of attention.
    Luck SJ; Ford JM; Sarter M; Lustig C
    Schizophr Bull; 2012 Jan; 38(1):53-61. PubMed ID: 21765166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cognitive neuroscience of memory function and dysfunction in schizophrenia.
    Ranganath C; Minzenberg MJ; Ragland JD
    Biol Psychiatry; 2008 Jul; 64(1):18-25. PubMed ID: 18495087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging biomarkers for treatment development for impaired cognition: report of the sixth CNTRICS meeting: Biomarkers recommended for further development.
    Carter CS; Barch DM;
    Schizophr Bull; 2012 Jan; 38(1):26-33. PubMed ID: 21914642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Executive functioning component mechanisms and schizophrenia.
    Kerns JG; Nuechterlein KH; Braver TS; Barch DM
    Biol Psychiatry; 2008 Jul; 64(1):26-33. PubMed ID: 18549874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation considerations for multisite clinical trials with cognitive neuroscience tasks.
    Keefe RS; Harvey PD
    Schizophr Bull; 2008 Jul; 34(4):656-63. PubMed ID: 18495645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.
    Beinat C; Banister SD; Herrera M; Law V; Kassiou M
    CNS Drugs; 2015 Jul; 29(7):529-42. PubMed ID: 26242477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.